Froome denies drug wrongdoing

British rider insists he broke no rules after 'adverse' doping test

PARIS - Four-time Tour de France winner Chris Froome said he has not broken any rules after returning an "adverse" drugs test result during his victory at this year's Vuelta a Espana.

Froome had twice the permissible amount of asthma medication Salbutamol in his system during the Grand Tour race which he won in September, the UCI and his team revealed on Wednesday.

"I understand this comes as a big shock to people," Froome said in an interview with the BBC published late on Wednesday.

"I certainly haven't broken any rules here."

Cycling's governing body UCI said an anti-doping test on Sept 7 showed more than the allowable level of Salbutamol which can be taken without needing a therapeutic use exemption (TUE).

The 32-year-old Froome told the BBC he simply upped his dosage on the advice of the team doctor after his asthma symptoms got worse.

"I have been treating my symptoms and racing with asthma for 10 years," said Froome.

"I know what those rules are, I know what those limits are and I have never been over those limits."

The UCI has asked Froome to provide more information but, in line with World Anti-Doping Agency guidelines, has not suspended him.

"I have got a very clear routine when I use my inhaler and how many times. I have given all that information to the UCI to help get to the bottom of it." He added the UCI was "absolutely right" to scrutinize the test results.

Froome's Team Sky said in a statement: "During the final week of the Vuelta, Chris experienced acute asthma symptoms. On the advice of the Team Sky doctor, he used an increased dosage of Salbutamol (still within the permissible doses) in the run-up to the September 7 urine test."

Sky said Froome had declared his use of the medication, adding: "The notification of the test finding does not mean that any rule has been broken."

The Briton, who also won Olympic time-trial bronze medals in 2012 and 2016, was notified of the test on Sept 20, the day he finished third in the world time-trial championship in Norway.

He has not competed since, but recently announced his intention to try to win two of cycling's three biggest races, the Tour de France and the Giro d'Italia, in 2018.

Unipublic, the company that runs the Vuelta, refused on Wednesday to take a negative stance on Froome saying they were waiting for the UCI to finish its probe before deciding whether to take any action against the champion.

"Our position is one of extreme prudence, and it is our hope that the matter will be resolved swiftly," Unipublic said on Wednesday.

'Not a great day'

Froome won the Vuelta on September 10, finishing 2 minutes and 15 seconds clear of Vicenzo Nibali, who was saddened by the news.

"It's not a great day for cycling and it's not a great day for him," said the Italian climber, who has won all three major cycling tours.

"If this test is confirmed it will not feel as if I climbed onto the highest step of the podium to be declared champion in Madrid," added the 2014 Tour de France winner.

Froome, widely considered the greatest Tour rider of his generation, is scheduled to race the Giro d'Italia in May next year ahead of defending his Tour de France title in July.

Sky's aim for next year was for Froome to join an exclusive group of riders who have held all three Grand Tour titles at the same time, and for him to clinch a record-equaling fifth Tour de France after his victories in 2013, 2015, 2016 and 2017.

The test has raised new questions about British cycling following the scandal surrounding Bradley Wiggins, who received TUEs to take a corticosteroid in 2011, 2012 and 2013, including before his 2012 Tour de France win. Wiggins and Sky have repeatedly denied any wrongdoing, saying the drug was prescribed to treat a long-standing pollen allergy.

In 2008 Italian sprinter Alessandro Petacchi was suspended for 12 months and stripped of five stage wins in the 2007 Giro d'Italia despite having a TUE for Salbutamol, having also exceeded the limit.

Agence France - presse